Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
| ▸ | CTSE | P14091 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2276486 | 0.83 | RORC (0.33) | KDM1A | |
| SCHEMBL4091330 | 0.74 | SLC6A4 (0.38) | — | |
| SCHEMBL4061370 | 0.72 | ELANE (0.81) | ELANEKDM1ACA2MAPKAPK2 | |
| SCHEMBL2366870 | 0.67 | ELANE (0.68) | ELANEKDM1ACA2MAPKAPK2 | |
| SCHEMBL7195551 | 0.67 | ELANE (0.68) | ELANEKDM1ACA2MAPKAPK2 | |
| SCHEMBL4059798 | 0.67 | ELANE (0.72) | ELANEKDM1ACA2MAPKAPK2 | |
| SCHEMBL30080569 | 0.66 | ELANE (0.66) | ELANEKDM1ACA2MAPKAPK2 | |
| SCHEMBL12228673 | 0.66 | ELANE (0.66) | ELANEKDM1ACA2MAPKAPK2 | |
| SCHEMBL4057059 | 0.66 | ELANE (0.70) | ELANEKDM1ACA2 | |
| SCHEMBL7195555 | 0.66 | ELANE (0.70) | ELANEKDM1ACA2MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP26, MMP11 | ELANE 427/4885KDM1A 443/4885CA2 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.